Eva Kras, M.S., joined Nurix in 2023 and has served as Vice President and Head of Regulatory Affairs since February 2024. Ms. Kras has over 22 years of experience in drug development, spanning early to late-stage programs across several therapeutic areas, including oncology/hematology and rare disease. Throughout her career, she has been responsible for developing innovative regulatory strategies leading to numerous global regulatory marketing approvals. Prior to joining Nurix, she held a variety of roles at Amgen, Seattle Genetics, BioMarin, GSK, Coherus and most recently BeiGene. Ms. Kras earned her B.S. in Pharmacology from the University of California, Santa Barbara, and her M.S. in Regulatory Science from the USC School of Pharmacy.
'